Study of allogeneic stem cell transplantation for pediatric acute myeloid leukemia

doi:10.3969/j.issn.1006-7795.2019.02.002

Abstract

Abstract: Objective To analysis the effectiveness of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treatment of children with acute myeloid leukemia (AML), and to identify the possible prognostic factors for treatment. Methods We retrospectively reviewed outcomes of children with AML who underwent allo-HSCT at Hematology Oncology Center of Beijing Children's Hospital, Capital Medical University between January of 2006 and January of 2016. The overall survival (OS) were estimated by Kaplan-Meier method, Log-rank test was used to compare the different groups and prognostic factors were evaluated by Cox regression. Results A total of 46 patients were involved, with 31 patients survived, and 15 patients died, 8 patients relapsed, with an average follow-up time of 27 months. 5 years OS was (61.1±8.7)%, median survival time was 77.3 months, and 5 years cumulative relapse rate was(16.0±6.0)%. The results of Log-rank test indicated no significant difference (P>0.05) with different protocol, remission state, remission times, graft versus-host disease (GVHD) and donors. The Cox regression suggested myeloid sarcoma and the relapse are the prognostic factors (P<0.05). Conclusion Allogeneic hematopoietic stem cell transplantation is an effective treatment for AML, especially, refractory/relapsed AML. With the modified conditioning regimen and supportive treatment, the survival rate is increasing year by year. Myeloid sarcoma and relapse are important adverse prognostic factors of HSCT treatment for AML.

Key words: stem cell transplantation, acute myeloid leukemia, pediatric

CLC Number:

R733

Jia Chenguang, Zhou Xuan, Wang Bin, Zhu Guanghua, Qin Maoquan. Study of allogeneic stem cell transplantation for pediatric acute myeloid leukemia[J]. Journal of Capital Medical University, 2019, 40(2): 163-168.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.02.002

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I2/163

References

[1] Creutzig U, Zimmermann M, Bourquin J P, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia:Results from Study AML-BFM 2004[J]. Blood,2013, 122(1):37-43.
[2] Cooper T M, Franklin J, Gerbing R B, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia:A report from the Children's Oncology Group[J]. Cancer,2012, 118, 761-769.
[3] Pession A, Masetti R, Rizzari C, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia[J]. Blood,2013, 122(2):170-178.
[4] Gibson B E, Webb D K, Howman A J, et al. United kingdom childhood leukaemia working group; the dutch childhood oncology group. results of a randomized trial in children with acute myeloid leukaemia:medical research council AML12 trial[J]. Br J Haematol, 2011, 155(3):366-376.
[5] Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate[J]. J Clin Oncol, 2011, 29(3):310-315.
[6] 江载芳,申昆玲,沈颖. 诸福棠实用儿科学[M]. 8版. 北京:人民卫生出版社,2015:2361-2365.
[7] O'Donnell M R,Tallman M S,Abboud C N,et al. Acute myeloid leukemia,version 2.2013[J].J Natl Compr Canc Netw,2013,11(9):1047-1055.
[8] Wang Y, Liu D H, Xu L P, et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia:a retrospective risk-factor analysis[J]. Bone Marrow Transplant,2012, 47(8):1099-1104.
[9] Liu D H, Xu L P, Liu K Y, et al. Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia[J]. Bone Marrow Transplantation, 2013, 48(12):1519-1524.
[10] Niewerth D, Creutzig U, Bierings M B, et al. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia[J]. Blood, 2010, 116(13):2205-2214.
[11] Leung W, Pui C H, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia[J]. Blood, 2012,120(2):468-472.
[12] Chevallier P, Mohty M, Lioure B, et al. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma:a retrospective study from the SFGM-TC[J]. J Clin Oncol, 2008,26(30):4940-4943.
[13] Wang Y, Chang Y J, Xu L P, et al. Who is the best donor for a related HLA haplotype-mismatched transplant?[J]. Blood, 2014, 124(6):843-850.
[14] Yan C H, Liu D H, Liu K Y, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation[J]. Blood,2012,119(14):3256-3262.